Celgene Corporation

United States of America


Create a watch for Celgene Corporation
Total IP 1,405
Total IP incl. subs 1,974 (+ 569 for subs)
Total IP Rank # 967
IP Activity Score 3.6/5.0    817
IP Activity Rank # 896
IP AS incl. subs 3.3/5.0    891
Stock Symbol CELG (nasdaq)
ISIN US1510201049
Market Cap. 77,036M  (USD)
Industry Drug Manufacturers - Major
Sector Healthcare
Dominant Nice Class Pharmaceutical, veterinary and s...

Patents

Trademarks

371 186
98 208
331 69
142
 
Last Patent 2025 - Method for predicting response t...
First Patent 1981 - Production of muconic acid
Last Trademark 2025 - ZENBEKEBI & Fin Design
First Trademark 1996 - Rev

Subsidiaries

20 subsidiaries with IP (549 patents, 20 trademarks)

9 subsidiaries without IP

 Register for free to unlock the subsidiary list

Industry (Nice Classification)

Latest Inventions, Goods, Services

2025 G/S Pharmaceutical and biological preparations for human use.
G/S Pharmaceutical and biological preparations for human use.
G/S Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases,...
Invention Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl...
G/S Pharmaceutical preparations for the treatment and prevention of oncological, hematological, metab...
Invention Modulators of bcl6 as ligand directed degraders. Provided herein are compounds and compositions ...
Invention Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidi...
Invention Heterocyclic compounds and their use for treatment of helminthic infections and diseases. Provid...
Invention Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morphol...
2024 Invention Therapy for the treatment of multiple myeloma. Provided herein are methods of treating and/or man...
Invention Antiproliferative compounds and second active agents for combined use. Provided herein are metho...
G/S Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinen...
G/S Pharmaceutical and biological preparations for human use in the fields of hematology, oncology an...
Invention Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-mor...
Invention Uses of anti-bcma chimeric antigen receptors. Provided herein are uses of anti-B cell maturation...
Invention Combination therapies comprising apremilast and tyk2 inhibitors. Provided herein are methods of ...
Invention Oral formulations of cytidine analogs and methods of use thereof. The present disclosure provide...
Invention Cereblon binding compounds, compositions thereof, and methods of treatment therewith. Provided h...
Invention Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin...
Invention Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of cli...
Invention Antiproliferative compounds and bispecific antibody against bcma and cd3 for combined use. Provi...
Invention Tablet compositions. Provided herein is a tablet comprising 2-methyl-1-[(4-[6-(trifluoromethyl)p...
Invention Heteroaryl compounds as ligand directed degraders of irak4. Provided herein are compounds and com...
Invention Transgenic mouse expressing human cereblon. Provided are transgenic mice whose genome comprises ...
Invention Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatmen...
Invention Assessment of bcma in biological samples. Provided herein are methods for detection of soluble B-...
Invention Compounds and compositions for selective degradation of engineered proteins. Provided herein are...
Invention Compounds and compositions for selective degradation of engineered proteins. Provided herein are ...
Invention Compounds and compositions useful as degraders of mk2 kinase. The present disclosure provides com...
Invention Processes for the preparation of (s)-tert-butyl 4,5-diamino-5-oxopentanoate. Provided are process...
Invention Combination therapies using an anti-bcma antibody drug conjugate (adc) in combination with a gamm...
Invention Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases. ...
2023 Invention Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and met...
Invention Heterocyclic pad4 inhibitors. The disclosure generally relates to compounds of Formula I, compri...
Invention Method for predicting response to a t cell therapy. The present disclosure relates to methods fo...
Invention Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior ther...
Invention Methods and uses related to t cell therapy and production of same. Provided herein are uses of T...
Invention Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma. Pro...
2022 Invention Carboxylic acid containing indanyl compounds for the treatment of neurodegenerative diseases. Pr...
Invention Modulators of camkk2 as ligand directed degraders. Provided herein are compounds of formula (I) ...
Invention Process for preparing histone demethylase inhibitors. Provided herein are methods for preparing ...
Invention Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoaze...
Invention Methods of treating multiple myeloma using combination therapy. Provided herein are methods of u...
Invention Pkc-theta modulators. Disclosed are compounds, compositions and methods for treating disease, sy...
Invention Treatment of cancer with kdm4 inhibitors. Provided herein are compositions and methods for the t...
Invention Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation ...
Invention Methods for treating multiple myeloma. Provided herein are methods of treating multiple myeloma,...
2021 Invention Actriib ligand trap compositions and uses thereof. The present application relates to recombinant...